Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +75

Assessing Regeneron (REGN) After Recent Share Price Weakness And Strong Valuation Signals - simplywall.st

AI-generated analysis

πŸ“‰ REGN stock has declined 6.7% over the last 30 days and 8.7% year-to-date, trading around US$709.10.

πŸ“ˆ The company recorded a strong 30.2% total return over the past 12 months.

πŸ’° DCF analysis projects a fair value of US$2,092 per share based on cash flow estimates reaching $11.0b by 2035.

πŸ“Š Current free cash flow is approximately $3.9b for the trailing twelve months.

πŸ” The stock trades at a P/E of 16.3x, below the industry average of 17.8x and peer average of 21.9x.

🎯 Simply Wall St's proprietary Fair Ratio suggests a reasonable P/E of 24.4x for Regeneron.

πŸ’‘ The valuation gap implies the stock is undervalued by approximately 66.1% according to DCF models.

🧠 Valuation incorporates factors like earnings growth profile, profit margins, and specific company risks.

Bullish Signals
  • Regeneron is projected to generate $11.0b in free cash flow by 2035, indicating strong long-term financial health.
  • The current share price of ~$709 is significantly lower than the estimated intrinsic value of $2,092 derived from DCF modeling.
  • Regeneron trades at a discount to both its industry peers (16.3x P/E vs 21.9x) and the broader biotech sector (16.3x vs 17.8x).
  • The company maintains a 'flawless balance sheet' according to the analysis, suggesting low financial distress risk.
  • Simply Wall St's proprietary Fair Ratio of 24.4x indicates substantial upside potential relative to current market pricing.
Risk Factors
  • Recent share price weakness includes an 8.7% decline year-to-date and a 6.7% drop over the last month, which may concern short-term investors.
  • The article notes that recent headlines focus on mixed return figures, suggesting some market skepticism regarding current performance relative to peers.
Full Analysis
Regeneron Pharmaceuticals (REGN) is currently trading at approximately US$709.10, reflecting a recent 30-day decline of 6.7% and an 8.7% drop year-to-date, despite a strong 30.2% return over the past year. The article analyzes whether this price weakness presents a buying opportunity or if the stock already reflects its value, noting that recent headlines often focus on the company's position within large-cap biotech and its pipeline progress. Simply Wall St employs two primary valuation methodologies to assess REGN: Discounted Cash Flow (DCF) analysis and Price vs. Earnings (P/E) comparison. The DCF model, utilizing a 2 Stage Free Cash Flow to Equity approach with a projected free cash flow of $11.0b by 2035, estimates an intrinsic fair value of roughly US$2,092 per share. This suggests the stock is currently trading at a significant discount, approximately 66.1% below its calculated intrinsic value. A P/E ratio analysis further supports the undervaluation thesis. Regeneron's current P/E stands at 16.3x, which is lower than both the Biotechs industry average of 17.8x and the peer group average of 21.9x. Simply Wall St calculates a proprietary 'Fair Ratio' of 24.4x based on earnings growth profiles and specific risks, indicating that the current market price trades well below this indicated reasonable level.